Full Press Release Details
Announces the Expansion of its Oncology Portfolio
The Agreement Substantially Increases Procaps'
Participation in the Oncology Market in the LatAm Region
MIAMI, USA - BARRANQUILLA, COL - September 7, 2023 -
Procaps Group, S.A. (NASDAQ: PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical
services company, announced today that it has entered into an agreement with BDR Pharmaceuticals International Pvt. Limited ("BDR
Pharmaceuticals") for 27 oncology molecules for Latin America, including 20 TKIs (Tirosyne Kinase Inhibitors).
Under the agreement, Procaps is responsible for
registration, branding, marketing and commercialization throughout Latin America. Procaps submitted an initial set of 8 molecules to the
regulatory authority in Colombia and intends to later expand into other parts of Latin America.
"We are very excited to expand our oncology
portfolio in the region and add more partner companies and potentially broaden cancer treatment options with several new molecules to
better serve more patients and physicians with this serious and growing disease," said Ruben Minski, CEO of Procaps Group.
Oncology is one of the most relevant therapeutic
areas globally, with a growing trend in Latin America driven by the aging and growth of the population and improvements in cancer survival
rates. According to the International Agency for Research on Cancer, by 2040 the number of cancer cases in Central and South America is
projected to increase by 91.4% and 76.5%, respectively, mostly due to lifestyle factors, ageing, screening, and infection-related cancers.
The Latin American regions where Procaps operates
has an aggregate population of approximately 204 million people, and the incidence of cancer affects around 0.3% of the population, which
is equivalent to approximately 500,000 new cases per year.
"These molecules are indicated for different
types of cancer such as breast cancer, colon cancer, and chronic myeloid leukemia, among others. Many of these molecules, if approved,
will likely be introduced to our region for the first time, which aligns with our mission to continue seeking to provide patients in Latin
America with potential alternative and accessible therapies," added Dr. Camilo Camacho, COO of Procaps Group
Procaps (NASDAQ: PROC) is a leading developer
of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents.
Procaps has a direct presence in 13 countries in the Americas and more than 5,500 employees working under a sustainable model. Procaps
develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products, prescription pharmaceutical drugs (Rx), nutritional
supplements, and high-potency clinical solutions.
For more information, visit www.procapsgroup.com
or Procaps' investor relations website investor.procapsgroup.com.
investor.procapsgroup.com
Forward Looking Statements
This press release includes "forward-looking
statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend,"
"seek," "target," "anticipate," "believe," "expect," "estimate,"
"plan," "outlook," and "project" and other similar expressions that predict or indicate future events
or trends or that are not statements of historical matters. Such forward-looking statements include projected financial information as
well as the benefits (if any) to be achieved by our agreement with BDR Pharmaceuticals, and there can be no assurance that any regulatory
approvals for the molecules underlying the agreement with BDR Pharmaceuticals will be obtained. A number of factors could cause actual
results or outcomes to differ materially from those indicated by such forward-looking statements. These forward-looking statements involve
a number of risks, uncertainties (some of which are beyond our control), or other assumptions that may cause actual results or performance
to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include,
but are not limited to, the risks included under the header "Risk Factors" in Procaps' annual report on Form 20-F filed
with the SEC, as well as Procaps' other filings with the SEC. Should one or more of these risks or uncertainties materialize, or
should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking
statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these